Citizens Jmp Forecasts Strong Price Appreciation for BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines (NASDAQ:ONC) had its price target hoisted by Citizens Jmp from $348.00 to $396.00 in a report released on Friday,Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. Citizens Jmp’s price target would suggest a potential upside of 24.81% from the company’s current price.

Other research analysts have also issued research reports about the stock. Wall Street Zen upgraded shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Friday, October 3rd. Royal Bank Of Canada boosted their price target on BeOne Medicines from $349.00 to $364.00 and gave the company an “outperform” rating in a research note on Thursday, August 7th. Morgan Stanley lifted their price objective on shares of BeOne Medicines from $350.00 to $383.00 and gave the company an “overweight” rating in a research note on Monday, October 20th. Zacks Research downgraded BeOne Medicines from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 28th. Finally, Guggenheim boosted their target price on shares of BeOne Medicines from $350.00 to $365.00 and gave the company a “buy” rating in a research note on Thursday, August 7th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $350.18.

BeOne Medicines Trading Down 4.5%

Shares of NASDAQ ONC traded down $15.07 during midday trading on Friday, hitting $317.29. The company’s stock had a trading volume of 35,843 shares, compared to its average volume of 389,623. BeOne Medicines has a 12-month low of $170.99 and a 12-month high of $355.30. The company has a current ratio of 1.95, a quick ratio of 1.72 and a debt-to-equity ratio of 0.04. The firm has a market cap of $34.79 billion, a P/E ratio of -183.40 and a beta of 0.31. The business’s 50 day moving average is $326.63 and its two-hundred day moving average is $287.14.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings data on Thursday, November 6th. The company reported $1.09 EPS for the quarter, beating the consensus estimate of $0.72 by $0.37. BeOne Medicines had a negative return on equity of 1.22% and a negative net margin of 3.89%.The company had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.34 billion. BeOne Medicines has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that BeOne Medicines will post -5.82 EPS for the current year.

Insiders Place Their Bets

In related news, insider Lai Wang sold 5,000 shares of the company’s stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $350.06, for a total value of $1,750,300.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO John Oyler sold 27,803 shares of the firm’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $325.71, for a total transaction of $9,055,715.13. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 157,074 shares of company stock valued at $49,396,898. Insiders own 6.62% of the company’s stock.

Institutional Investors Weigh In On BeOne Medicines

Large investors have recently added to or reduced their stakes in the business. Anchor Investment Management LLC purchased a new position in BeOne Medicines in the 2nd quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of BeOne Medicines in the second quarter valued at $28,000. Daiwa Securities Group Inc. purchased a new position in BeOne Medicines in the second quarter valued at $35,000. Farther Finance Advisors LLC acquired a new position in BeOne Medicines during the 2nd quarter worth $39,000. Finally, Signaturefd LLC acquired a new position in BeOne Medicines during the 2nd quarter worth $49,000. 48.55% of the stock is owned by hedge funds and other institutional investors.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.